334 related articles for article (PubMed ID: 27951564)
1. Preventive Strategies for Vascular Calcification in Patients with Chronic Kidney Disease.
Shigematsu T; Sonou T; Ohya M; Yokoyama K; Yoshida H; Yokoo T; Okuda K; Masumoto AR; Iwashita Y; Iseki K; Kunimoto S; Yamano Y
Contrib Nephrol; 2017; 189():169-177. PubMed ID: 27951564
[TBL] [Abstract][Full Text] [Related]
2. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
3. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
Spasovski G
Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
[TBL] [Abstract][Full Text] [Related]
4. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
5. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
6. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
7. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
8. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
[TBL] [Abstract][Full Text] [Related]
9. Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism.
McCabe KM; Zelt JG; Kaufmann M; Laverty K; Ward E; Barron H; Jones G; Adams MA; Holden RM
J Pharmacol Exp Ther; 2018 Sep; 366(3):433-445. PubMed ID: 29903718
[TBL] [Abstract][Full Text] [Related]
10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
11. Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease.
Lee SM; An WS
Korean J Intern Med; 2019 May; 34(3):459-469. PubMed ID: 31048656
[TBL] [Abstract][Full Text] [Related]
12. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
13. Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.
Latif F; Khalid MM; Khan F; Omar Z; Ali FA
J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):410-5. PubMed ID: 23392553
[TBL] [Abstract][Full Text] [Related]
14. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
Gross P; Six I; Kamel S; Massy ZA
Circ J; 2014; 78(10):2339-46. PubMed ID: 25077548
[TBL] [Abstract][Full Text] [Related]
15. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations.
Cozzolino M; Ketteler M; Wagner CA
Expert Opin Ther Targets; 2020 May; 24(5):477-488. PubMed ID: 32191548
[No Abstract] [Full Text] [Related]
16. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia. The hidden killer in chronic kidney disease.
Askar AM
Saudi Med J; 2015 Jan; 36(1):13-9. PubMed ID: 25629999
[TBL] [Abstract][Full Text] [Related]
18. Smooth Muscle-Selective Nuclear Factor-κB Inhibition Reduces Phosphate-Induced Arterial Medial Calcification in Mice With Chronic Kidney Disease.
Yoshida T; Yamashita M; Horimai C; Hayashi M
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29146611
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
20. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease.
Matsumoto T; Fukushima S; Kanasaki T; Hagino S
Biol Trace Elem Res; 2012 Dec; 150(1-3):278-84. PubMed ID: 22700181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
